Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Immun Inflamm Dis. 2023 Jul;11(7):e924. doi: 10.1002/iid3.924.
To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid.
From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes.
The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment.
Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
回顾性分析度普利尤单抗治疗大疱性类天疱疮的疗效和安全性。
回顾性收集 2020 年 10 月至 2022 年 10 月在我科接受度普利尤单抗治疗的大疱性类天疱疮患者的病历资料，分析治疗效果及实验室指标变化。
共 11 例大疱性类天疱疮患者应用度普利尤单抗治疗，治疗后 2 周内 10 例（90.9%）患者疾病完全或大部分得到控制。患者的 BPDAI 评分由基线的 113（62，181）分降至治疗后 2 周的 37（6，130）分（p = .001）和 12 周的 4（0，37）分（p < .001）。11 例患者应用度普利尤单抗治疗后瘙痒缓解时间为 0～3 天（0.5，7）天，治疗后 2 周瘙痒明显缓解（t = 15.925，p < .001）。DLQI 评分由治疗前的（25.5 ± 2.5）分降至治疗后 2 周的（11.8 ± 4.4）分（t = 10.764，p < .001）和 12 周的（2.1 ± 1.9）分（t = 30.038，p < .001）。患者均存在外周血嗜酸性粒细胞计数高、血清 IgE 水平高、血清总蛋白水平低、凝血功能异常，治疗后上述指标逐渐恢复正常。治疗过程中未发生不良反应。
度普利尤单抗能有效控制大疱性类天疱疮病情，有效缓解瘙痒症状，安全性较高。
